370 related articles for article (PubMed ID: 28755181)
1. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
2. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U; Dubois J; Mitchell GA
Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
[TBL] [Abstract][Full Text] [Related]
3. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
4. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
5. Hereditary Tyrosinemia Type 1 in Turkey.
Aktuglu-Zeybek AC; Kiykim E; Cansever MS
Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
[TBL] [Abstract][Full Text] [Related]
7. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
[TBL] [Abstract][Full Text] [Related]
8. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
9. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
[TBL] [Abstract][Full Text] [Related]
10. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
11. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
[TBL] [Abstract][Full Text] [Related]
12. Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1.
Elgilani F; Mao SA; Glorioso JM; Yin M; Iankov ID; Singh A; Amiot B; Rinaldo P; Marler RJ; Ehman RL; Grompe M; Lillegard JB; Hickey RD; Nyberg SL
Am J Pathol; 2017 Jan; 187(1):33-41. PubMed ID: 27855279
[TBL] [Abstract][Full Text] [Related]
13. Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.
Neuckermans J; Lequeue S; Claes P; Heymans A; Hughes JH; Colemonts-Vroninks H; Marcélis L; Casimir G; Goyens P; Martens GA; Gallagher JA; Vanhaecke T; Bou-Gharios G; De Kock J
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980965
[TBL] [Abstract][Full Text] [Related]
14. Liver Cancer in Tyrosinemia Type 1.
van Ginkel WG; Pennings JP; van Spronsen FJ
Adv Exp Med Biol; 2017; 959():101-109. PubMed ID: 28755188
[TBL] [Abstract][Full Text] [Related]
15. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
Morrow G; Angileri F; Tanguay RM
Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
[TBL] [Abstract][Full Text] [Related]
16. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
17. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress.
Dieter MZ; Freshwater SL; Miller ML; Shertzer HG; Dalton TP; Nebert DW
Free Radic Biol Med; 2003 Aug; 35(4):351-67. PubMed ID: 12899938
[TBL] [Abstract][Full Text] [Related]
19. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1.
Maiorana A; Malamisura M; Emma F; Boenzi S; Di Ciommo VM; Dionisi-Vici C
Mol Genet Metab; 2014 Nov; 113(3):188-93. PubMed ID: 25172236
[TBL] [Abstract][Full Text] [Related]
20. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
